Farxiga Geriatric (65+) Caregiver Administration Guidance

What Farxiga Does and Why Geriatric Physiology Changes the Risk Profile

Dapagliflozin blocks sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, causing the kidneys to excrete roughly 60 to 80 grams of glucose per day in urine. That glucosuria also pulls sodium and water with it, producing a mild osmotic diuresis. In healthy middle-aged adults the body compensates quickly. In adults over 65, compensatory mechanisms are blunted.

Age-Related Physiological Changes That Matter

Kidney mass declines roughly 1% per year after age 40, and glomerular filtration rate falls by approximately 0.75 to 1 mL/min/1.73 m² per year in adults without pre-existing renal disease. By age 75, a patient whose serum creatinine looks "normal" at 1.1 mg/dL may have an eGFR below 50 mL/min/1.73 m², which meaningfully reduces dapagliflozin's glycemic efficacy and simultaneously increases the risk of acute kidney injury during any intercurrent illness or dehydration event [1].

Thirst sensation also diminishes with age. A 2019 review in the Journal of Physiology documented that older adults show a 20 to 30% reduction in osmoreceptor sensitivity compared with younger cohorts, meaning they do not feel thirsty until dehydration is already clinically significant [2]. Caregivers cannot rely on the patient asking for water.

Postural Hemodynamics

Blood pressure regulation changes as arterial stiffness increases. Orthostatic hypotension, defined as a drop of at least 20 mmHg systolic or 10 mmHg diastolic within three minutes of standing, affects 20 to 30% of community-dwelling adults over 70 [3]. The osmotic diuresis from dapagliflozin reduces intravascular volume modestly but measurably, which may tip a borderline patient into symptomatic orthostasis. Falls are the leading cause of injury-related death in adults over 65 in the United States, with the CDC reporting 36 million falls annually in this age group [4].

Approved Dosing for Adults 65 and Older

No pharmacokinetic study has shown a clinically meaningful difference in dapagliflozin exposure by age alone. The FDA-approved prescribing information states no dose adjustment is required based on age [5]. The dose remains 5 mg once daily as a starting point, with titration to 10 mg once daily for additional glycemic lowering or for the heart failure indication.

eGFR Thresholds That Override Age

Renal function, not chronological age, is the true gating factor. The current labeling specifies:

• For type 2 diabetes glycemic control: initiation not recommended if eGFR <45 mL/min/1.73 m²; discontinue if eGFR falls and remains below 45.
• For heart failure with reduced ejection fraction (HFrEF): can be used down to eGFR <25 mL/min/1.73 m²; no lower eGFR limit is specified in the HF indication.
• For chronic kidney disease (CKD): indicated when eGFR is 25 to 75 mL/min/1.73 m²; evidence from DAPA-CKD (N=4,304) showed a 44% relative risk reduction in the composite of sustained 50% eGFR decline, end-stage kidney disease, or renal/cardiovascular death versus placebo [6].

Caregivers should request a printed copy of the patient's most recent eGFR from the prescribing provider and update it in a medication log that stays with the pill organizer.

Timing and Administration Mechanics

Give dapagliflozin at the same time every day. Morning administration is preferred in older adults because the osmotic diuresis peaks within two to four hours of dosing; taking the tablet in the morning means the peak diuresis occurs during waking hours rather than overnight. Nocturia in a 70+ patient raises fall risk substantially, and a 2020 analysis in the Journal of Urology found that each nocturia episode per night was associated with a 21% increase in fall probability [7].

The tablet can be given with or without food. Swallow whole with at least 240 mL (8 oz) of water. For patients with dysphagia, confirm with the dispensing pharmacist whether the tablet may be crushed, because the current manufacturer formulation has not been studied in crushed form and bioavailability data are not available.

Step-by-Step Caregiver Administration Protocol

The following protocol applies to adults 65 and older who are dependent on caregiver assistance for medication management.

Before Each Dose: A 60-Second Safety Check

1. Ask the patient or check the night output record: did they urinate at least once overnight? Oliguria (less than 500 mL/day total) is a red flag for dehydration or early AKI.
2. Take a seated blood pressure if a cuff is available. If systolic is below 100 mmHg, hold the dose and call the prescriber.
3. Confirm the patient has consumed at least 120 mL of fluid in the preceding two hours.
4. Check skin turgor on the back of the hand and inspect oral mucosa for dryness.

Administering the Tablet

Place the tablet in the patient's dominant hand or use a pill-splitting cup if grip strength is impaired. Hand the water glass immediately. Watch for swallowing completion. For patients on feeding tubes, consult the pharmacist: dapagliflozin tablets are not approved for tube administration.

After Each Dose: Hydration Target

The American Diabetes Association 2024 Standards of Care recommend proactive fluid management in older adults on SGLT2 inhibitors, particularly during hot weather, febrile illness, or gastrointestinal illness [8]. A practical target for most older adults is 1,500 to 2,000 mL of total fluid per day, adjusted downward if the patient has heart failure with a physician-prescribed fluid restriction. Log fluid intake in a daily sheet and share the log at each clinic visit.

Recognizing and Responding to High-Risk Complications

Volume Depletion and Acute Kidney Injury

The DECLARE-TIMI 58 trial (N=17,160) reported that dapagliflozin did not significantly increase the rate of acute kidney injury versus placebo overall, but the event rate in patients over 65 who were also on a loop diuretic was numerically higher [9]. Practical rule: if the patient reports vomiting or diarrhea for more than 12 hours, hold dapagliflozin and call the prescriber that day. NSAIDs, contrast dye procedures, and any new nephrotoxic antibiotic are also reasons to hold the drug until the prescriber confirms it is safe to resume.

Warning signs of dehydration requiring same-day medical contact:

• Confusion or new cognitive blunting
• Dry mouth and no tears when crying
• Heart rate above 100 bpm at rest
• Systolic blood pressure drop of more than 20 mmHg on standing

Urinary Tract Infections

Glucosuria creates a favorable environment for bacterial growth. The FDA label for dapagliflozin includes a warning about serious urinary tract infections, including urosepsis and pyelonephritis [5]. Older women are at the highest baseline risk. Caregivers should check for:

• Increased urgency or frequency beyond the expected glucosuria-related effect
• Cloudy or foul-smelling urine
• Fever above 38°C (100.4°F)
• New or worsening confusion, which in older adults is often the only UTI symptom

Any suspected UTI in a patient on dapagliflozin warrants a call to the prescriber rather than a wait-and-see approach. Untreated UTIs in SGLT2 inhibitor users can ascend rapidly.

Fournier's Gangrene (Necrotizing Fasciitis of the Perineum)

This is rare but life-threatening. The FDA added a boxed warning for SGLT2 inhibitors after identifying 12 cases in post-marketing surveillance through 2018 [5]. Caregivers assisting with perineal hygiene should inspect for unusual redness, swelling, or tenderness between the genitals and the anus. Any such finding is a 911-level emergency.

Euglycemic Diabetic Ketoacidosis

Euglycemic DKA can occur with dapagliflozin even when blood glucose appears normal or only mildly elevated. Risk is highest after major surgery, prolonged fasting, or a very low-carbohydrate diet. Symptoms include nausea, vomiting, abdominal pain, and malaise. A blood glucose of 180 mg/dL does not rule out DKA in a patient on an SGLT2 inhibitor [10]. If the patient is scheduled for surgery, confirm with the surgical team: standard guidance from the ADA recommends holding SGLT2 inhibitors at least three to four days before any procedure requiring general anesthesia [8].

Drug Interactions Caregivers Must Know

Older adults take an average of five prescription medications concurrently, and polypharmacy amplifies dapagliflozin-related risks [11].

Diuretic Combinations

Loop diuretics (furosemide, torsemide, bumetanide) combined with dapagliflozin produce additive volume depletion. If the patient's loop diuretic dose was recently increased, notify the dapagliflozin prescriber. The two drugs are not contraindicated together; their combination is actually intentional in some HFrEF protocols, but it requires closer monitoring of renal function and electrolytes.

Renin-Angiotensin System Blockers

ACE inhibitors (lisinopril, enalapril) and ARBs (losartan, valsartan) reduce renal perfusion pressure. Together with SGLT2 inhibitor-driven volume contraction, this triple combination (RAAS blocker plus diuretic plus dapagliflozin) significantly elevates AKI risk. The prescriber should re-check a BMP within two to four weeks of adding dapagliflozin to this regimen.

Insulin and Sulfonylureas

Dapagliflozin alone has negligible hypoglycemia risk. Add insulin or a sulfonylurea (glipizide, glimepiride, glyburide) and hypoglycemia becomes a concern, particularly in older adults who may not recognize adrenergic warning signs reliably. Target glucose range should be explicitly confirmed with the prescriber; the ADA's Older Adults Standards recommend less stringent HbA1c targets of 7.5% to 8.0% for adults with multiple chronic conditions, with avoidance of hypoglycemia as a primary goal [8].

Monitoring Schedule for Caregivers and Clinicians

The table below synthesizes current FDA labeling, ADA 2024 Standards, and the DAPA-HF and DAPA-CKD trial monitoring protocols into a practical geriatric-specific schedule.

| Monitoring Item | Frequency | Action Threshold | |---|---|---| | eGFR and creatinine | Every 3 months for first year, then every 6 months | Hold for eGFR <45 (T2D); reassess dose for rapid decline | | Blood pressure (seated and standing) | Every clinic visit; weekly at home if new orthostasis | Systolic <100 mmHg: hold dose, call prescriber | | Electrolytes (Na, K, Mg) | Every 3-6 months | Hyponatremia <130 mEq/L: urgent prescriber contact | | Urine dipstick for nitrites/leukocyte esterase | Only when UTI symptoms present | Positive result: prescriber contact same day | | Perineal skin inspection | Weekly during personal hygiene assistance | Any erythema, swelling, or tenderness: emergency services | | Weight (fluid status) | Daily in HF patients; weekly in others | 2 kg gain in 24 hours: prescriber contact | | HbA1c | Every 3 months until at goal, then every 6 months | Adjust based on individualized target |

Practical Caregiver Communication Script

When calling the prescriber's office, use this framework to communicate efficiently:

"I am calling about [patient name], date of birth [DOB], who takes Farxiga [dose] mg once daily. Today I am observing [specific symptom or measurement]. The patient's most recent eGFR on file is [value] from [date]. I am asking whether to give today's dose and whether any lab work is needed today."

Providing the eGFR date upfront typically halves the callback time and allows the on-call provider to make a faster, safer decision. Most practices have a nurse triage line that can handle these calls without a physician callback if the information is complete.

Special Scenarios in Geriatric Care Settings

Nursing Home and Assisted-Living Administration

In skilled nursing facilities, dapagliflozin falls under the same medication administration record (MAR) workflow as any oral agent. Federal regulations under 42 CFR Part 483 require facilities to implement a drug regimen review monthly. Caregivers administering medications in these settings should flag dapagliflozin for the consulting pharmacist's quarterly review, particularly if the patient's weight, appetite, or renal function has changed since admission.

Hospice and Comfort-Care Settings

Dapagliflozin has no analgesic or symptom-relief property. In patients transitioned to comfort-focused care, the drug's continued use should be reassessed by the palliative care team. The American Academy of Hospice and Palliative Medicine does not recommend continuing SGLT2 inhibitors when glycemic control is no longer a quality-of-life goal. Discontinuation typically requires no taper; the drug can be stopped abruptly.

Cognitive Impairment and Medication Adherence

Patients with dementia cannot reliably self-administer medications. A caregiver in this context must manage every step of the protocol above. The DAPA-HF trial (N=4,744) did not stratify by cognitive status, but the overall 26% relative risk reduction in the composite of worsening heart failure or cardiovascular death [12] still applies to older adults with dementia who have HFrEF, provided the caregiver can ensure the monitoring described above.

When to Permanently Discontinue Farxiga

Stop dapagliflozin and do not restart without explicit prescriber instruction in these situations:

• eGFR falls below the indication-specific threshold and remains there on two consecutive measurements at least two weeks apart.
• Recurrent urinary tract infections (two or more per year) directly temporally linked to dapagliflozin use.
• Patient develops type 1 diabetes or a confirmed history of DKA on the drug.
• Patient is admitted to the hospital for any reason: the standard of care in most hospital systems is to hold all SGLT2 inhibitors on admission and reassess at discharge [8].
• Patient is scheduled for surgery: hold for a minimum of three to four days pre-operatively as noted above.

The prescriber should document the discontinuation reason in the chart. Caregivers should request a printed updated medication list at each care transition, because SGLT2 inhibitors are among the most commonly re-started erroneously after a hospital-ordered hold.

The FDA label specifies that dapagliflozin is not recommended for patients with eGFR persistently below 25 mL/min/1.73 m² under the CKD indication, and not for use in type 1 diabetes [5]. A caregiver who observes any discrepancy between these thresholds and the current prescription should raise the concern directly with the pharmacist or prescriber before administering the next dose.